Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and Ofatumumab in Previously Untreated CLL
NCT01361711Phase 2Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Jun 2011
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by Northwestern University. Primary endpoint: Best Response as Defined by the iwCLL2008. Started Jun 2011; status: active, not recruiting.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01361711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01361711.